**Pediatric Grand Rounds**

**Course No. 19D30**

**Tuesday, April 23, 2019**

**8:00 – 9:00 am**

**\* \* \* Schusterman Learning Center, 1st Floor, Rm 145\* \* \***

**“Pharmacogenomics: A Missing Piece in the Pharmacotherapy Puzzle”**- - - - - - - - - - - - - - - - - - - -

**Presented by:**

**Samie Sabet, PharmD, BCPS, AE-C, Assistant Professor,   
Department of Pediatrics, OU-TU School of Community Medicine**

**Professional Practice Gaps:**

Recognition of availability and utility and incorporation of pharmacogenomics testing in pharmacotherapeutic management of pediatric conditions. Pediatric research and clinical implementation in pharmacogenetics lag behind corresponding adult discovery and clinical applications.

**Learning Objectives** - Upon completion of this session, participants will improve their competence and performance by being able to:

1. Describe the role of pharmacogenomics in optimizing medication therapy.
2. Review and interpret a sample pharmacogenomics test results.
3. List commonly used pediatric medications that have pharmacogenomics recommendations.
4. List and navigate resources available to guide pharmacotherapy decisions based on pharmacogenomics test results.

**Accreditation Statement**: The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Conflict Resolution Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [bjm@ou.edu](mailto:bjm@ou.edu), or visit [www.ou.edu/eoo.](http://www.ou.edu/eoo.html)

**Accommodation Statement:** For accommodation, please contact (918) 660-3424.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Faculty and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also discloses discussions of unlabeled/ unapproved uses of drugs or devices during their presentation(s).   
**Acknowledgement of Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Disclosure & Resolution  Report** | | | | | |  |
| The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activities disclosure information. | | | | | |  |
|  |
|  | | | **Nature of Relevant Financial Relationship** | | |  |
| **Role** | **First Name** | **Last Name** | **Commercial Interest** | **What was received?** | **For what role?** |  |
| Course Director/Moderator | Keith | Mather, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. | | |  |
| COURSE CONTACT | Jenna | Tow | I have no relevant financial relationships or affiliations with commercial interests to disclose. | | |  |
| Planning Committee | Jeanne | Hayes, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. | | |  |
| Speaker | Samie | Sabet, PharmD | I have no relevant financial relationships or affiliations with commercial interests to disclose. | | |  |